Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IB160-adjuvanted inactivated trivalent influenza vaccine
- Development stage
- Unknown
- Lead developer
- Instituto Butantan
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The IB160-adjuvanted inactivated trivalent influenza vaccine (internal code: VII3a-IB) is a vaccine candidate developed by Instituto Butantan for the prevention of seasonal influenza, particularly in older adults (aged 60 and older). The vaccine consists of a split-virion, inactivated trivalent influenza antigen propagated in embryonated eggs, combined with IB160, a proprietary squalene-based oil-in-water emulsion adjuvant developed by Instituto Butantan that is compositionally similar to MF59. It targets the hemagglutinin (HA) surface protein of influenza viruses to elicit protective antibody responses. The vaccine is currently in Phase III clinical development in Brazil, where it is being evaluated for non-inferiority to a high-dose inactivated trivalent influenza vaccine.
- Other names
- trivalent influenza vaccine adjuvanted with IB160Butantan adjuvanted trivalent influenza vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on IB160-adjuvanted inactivated trivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IB160-adjuvanted inactivated trivalent influenza vaccine.